Orchestra BioMed Holdings (OBIO) EBT (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly EBT of -$24.8 million for Q1 2026, down 27.72% year-over-year from -$34.2 million in Q1 2025, and down 487.22% quarter-over-quarter from $6.4 million in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) EBT (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported EBT for 6 consecutive years, with -$24.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 27.72% year-over-year to -$24.8 million; the TTM figure through Mar 2026 stood at -$60.5 million (up 22.77% YoY), while the FY2025 annual figure was -$160.1 million, down 1.18% from the prior year.
- EBT fell to -$24.8 million in Q1 2026 per OBIO's latest filing, from $6.4 million in the prior quarter.
- Across five years, EBT topped out at $6.4 million in Q4 2025 and bottomed at -$25.2 million in Q2 2024.
- Historically, EBT has averaged -$14.8 million across 5 years, with a median of -$16.1 million in 2024.
- Annual changes were most pronounced in 2022 — EBT plunged 8300.5% — and 2025, when it soared 139.71%.
- Orchestra BioMed Holdings' EBT stood at -$10.1 million in 2022, then fell by 23.72% to -$12.5 million in 2023, then decreased by 28.98% to -$16.1 million in 2024, then surged by 139.71% to $6.4 million in 2025, then tumbled by 487.22% to -$24.8 million in 2026.
- Business Quant data shows OBIO's EBT at -$24.8 million in Q1 2026, $6.4 million in Q4 2025, and -$20.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Orchestra BioMed Holdings | 323.53 Mn | 129.00 Mn | 63,000.00 | -24.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.12 Mn |
| Mar 31, 2026 | -22.90 Mn |
| Dec 31, 2025 | 5.99 Mn |
| Sep 30, 2025 | -20.83 Mn |
| Jun 30, 2025 | -19.36 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Dec 31, 2024 | -16.16 Mn |
| Sep 30, 2024 | -15.43 Mn |
| Jun 30, 2024 | -15.96 Mn |
| Mar 31, 2024 | -13.41 Mn |
| Dec 31, 2023 | -11.37 Mn |
| Sep 30, 2023 | -13.61 Mn |
| Jun 30, 2023 | -12.96 Mn |
| Mar 31, 2023 | -11.55 Mn |
| Dec 31, 2022 | -9.83 Mn |
| Sep 30, 2022 | -10.07 Mn |
| Jun 30, 2022 | -7.63 Mn |
| Mar 31, 2022 | -5.13 Mn |
| Dec 31, 2021 | -92,045.00 |
| Sep 30, 2021 | -94,445.00 |